Literature DB >> 10079207

ATP-Dependent colchicine transport by human erythrocyte glutathione conjugate transporter.

S Awasthi1, S S Singhal, U Pandya, S Gopal, P Zimniak, S V Singh, Y C Awasthi.   

Abstract

We have recently demonstrated mutually inhibitory ATP-dependent transport of dinitrophenyl-S-glutathione (DNP-SG) and doxorubicin by DNP-SG ATPase purified from human erythrocyte membranes (S. Awasthi et al., 1998a,b). Our previous studies indicate a broad substrate specificity for this transport mechanism, including some P-glycoprotein substrates. Present studies were carried out to determine whether colchicine (COL), a classical P-glycoprotein substrate, could be transported by purified human erythrocyte DNP-SG ATPase reconstituted in artificial liposomes. We also investigated whether leukotriene C4 (LTC4), an endogenous proinflammatory glutathione-conjugate derived from arachidonic acid, would inhibit colchicine transport. Uptake of COL was compared in proteoliposomes reconstituted with the purified DNP-SG ATPase as well as control liposomes in the presence or absence of ATP. Increased colchicine uptake was observed upon addition of ATP to proteoliposomes, but not control liposomes. Uptake was linear with respect to the amount of vesicle protein used. Sensitivity to osmolarity was consistent with intravesicular COL accumulation. The ATP-dependent colchicine uptake was sensitive to temperature in a manner consistent with a protein-mediated transport process with activation energy of 7.3 kcal/mol. Time-dependent COL uptake by proteoliposomes in the presence of ATP was consistent with a single compartment model with an apparent rate constant of 0.21 +/- 0.02 min-1. Kinetic studies indicated a saturable behavior with respect to ATP (Km 2.3 +/- 0.7 mM) and colchicine (Km 4.3 +/- 0.2 microM). LTC4 was found to be a competitive inhibitor of COL transport (Kis 16.4 microM). Since DNP-SG ATPase is present in many tissues, it may play an important role in determining colchicine accumulation in cells. Increased LTC4 would tend to increase cellular COL accumulation. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10079207     DOI: 10.1006/taap.1998.8617

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  9 in total

Review 1.  Role of RLIP76 in doxorubicin resistance in lung cancer.

Authors:  Rit Vatsyayan; Pankaj Chaudhary; Poorna Chandra Rao Lelsani; Preeti Singhal; Yogesh C Awasthi; Sanjay Awasthi; Sharad S Singhal
Journal:  Int J Oncol       Date:  2009-06       Impact factor: 5.650

2.  Knockdown of RLIP76 expression by RNA interference inhibits invasion, induces cell cycle arrest, and increases chemosensitivity to the anticancer drug temozolomide in glioma cells.

Authors:  Qi Wang; Jun Qian; Junyu Wang; Chun Luo; Juxiang Chen; Guohan Hu; Yicheng Lu
Journal:  J Neurooncol       Date:  2013-01-06       Impact factor: 4.130

3.  Prediction of Drug Permeability Using In Vitro Blood-Brain Barrier Models with Human Induced Pluripotent Stem Cell-Derived Brain Microvascular Endothelial Cells.

Authors:  Makiko Ohshima; Shota Kamei; Hideo Fushimi; Shinji Mima; Tadanori Yamada; Takeshi Yamamoto
Journal:  Biores Open Access       Date:  2019-11-14

Review 4.  RLIP76: A novel glutathione-conjugate and multi-drug transporter.

Authors:  Sharad S Singhal; Sushma Yadav; Cherice Roth; Jyotsana Singhal
Journal:  Biochem Pharmacol       Date:  2008-10-15       Impact factor: 5.858

5.  Diminished drug transport and augmented radiation sensitivity caused by loss of RLIP76.

Authors:  Sharad S Singhal; Sushma Yadav; Jyotsana Singhal; Mukesh Sahu; Archana Sehrawat; Sanjay Awasthi
Journal:  FEBS Lett       Date:  2008-09-18       Impact factor: 4.124

Review 6.  RLIP76 and Cancer.

Authors:  Sanjay Awasthi; Sharad S Singhal; Yogesh C Awasthi; Bryan Martin; Jung-Hee Woo; C Casey Cunningham; Arthur E Frankel
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

Review 7.  RLIP76: a versatile transporter and an emerging target for cancer therapy.

Authors:  Rit Vatsyayan; Poorna Chandra Rao Lelsani; Sanjay Awasthi; Sharad S Singhal
Journal:  Biochem Pharmacol       Date:  2010-01-25       Impact factor: 5.858

8.  Hsf-1 and POB1 induce drug sensitivity and apoptosis by inhibiting Ralbp1.

Authors:  Sharad S Singhal; Sushma Yadav; Kenneth Drake; Jyotsana Singhal; Sanjay Awasthi
Journal:  J Biol Chem       Date:  2008-05-12       Impact factor: 5.157

9.  Emerging treatments in lung cancer - targeting the RLIP76 molecular transporter.

Authors:  Lawrence E Goldfinger; Seunghyung Lee
Journal:  Lung Cancer (Auckl)       Date:  2013
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.